Delivery of Therapeutic Oligonucleotides in Nanoscale

Overview

Journal Bioact Mater

Specialty Biomedical Engineering

Date 2021 Sep 1

PMID 34466734

Citations 22

Authors

Lei Wu

Wenhui Zhou

Lihua Lin

Anhong Chen

Jing Feng

Xiangmeng Qu

Hongbo Zhang

Jun Yue

Affiliations

Soon will be listed here.

Abstract

Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in the targeted cancer treatment due to their high specificity and capability of modulating cellular pathways that are not readily druggable. However, efficiently delivering of TOs to cancer cellular targets is still the biggest challenge in promoting their clinical translations. Emerging as a significant drug delivery vector, nanoparticles (NPs) can not only protect TOs from nuclease degradation and enhance their tumor accumulation, but also can improve the cell uptake efficiency of TOs as well as the following endosomal escape to increase the therapeutic index. Furthermore, targeted and on-demand drug release of TOs can also be approached to minimize the risk of toxicity towards normal tissues using stimuli-responsive NPs. In the past decades, remarkable progresses have been made on the TOs delivery based on various NPs with specific purposes. In this review, we will first give a brief introduction on the basis of TOs as well as the action mechanisms of several typical TOs, and then describe the obstacles that prevent the clinical translation of TOs, followed by a comprehensive overview of the recent progresses on TOs delivery based on several various types of nanocarriers containing lipid-based nanoparticles, polymeric nanoparticles, gold nanoparticles, porous nanoparticles, DNA/RNA nanoassembly, extracellular vesicles, and imaging-guided drug delivery nanoparticles.

Citing Articles

Cationic Serine-Based Gemini Surfactant:Monoolein Aggregates as Viable and Efficacious Agents for DNA Complexation and Compaction: A Cytotoxicity and Physicochemical Assessment.

Oliveira I, Silva S, Gomes A, Real Oliveira M, Vale M, Marques E J Funct Biomater. 2024; 15(8).

PMID: 39194661 PMC: 11355309. DOI: 10.3390/jfb15080224.

Macromolecular Polymer Based Complexes: A Diverse Strategy for the Delivery of Nucleotides.

Singh D Protein Pept Lett. 2024; 31(8):586-601.

PMID: 39177133 DOI: 10.2174/0109298665310091240809103048.

Super-enhancer omics in stem cell.

Ma H, Qu J, Pang Z, Luo J, Yan M, Xu W Mol Cancer. 2024; 23(1):153.

PMID: 39090713 PMC: 11293198. DOI: 10.1186/s12943-024-02066-z.

Role of miRNA‑122 in cancer (Review).

Zhang J, Wu L, Ding R, Deng X, Chen Z Int J Oncol. 2024; 65(3).

PMID: 39027994 PMC: 11299766. DOI: 10.3892/ijo.2024.5671.

Emerging Perspectives on Prime Editor Delivery to the Brain.

BenDavid E, Ramezanian S, Lu Y, Rousseau J, Schroeder A, Lavertu M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931430 PMC: 11206523. DOI: 10.3390/ph17060763.

References

Wasungu L, Hoekstra D . Cationic lipids, lipoplexes and intracellular delivery of genes. J Control Release. 2006; 116(2):255-64. DOI: 10.1016/j.jconrel.2006.06.024. View

Rana S, Yue S, Stadel D, Zoller M . Toward tailored exosomes: the exosomal tetraspanin web contributes to target cell selection. Int J Biochem Cell Biol. 2012; 44(9):1574-84. DOI: 10.1016/j.biocel.2012.06.018. View

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002; 133(4):467-74. DOI: 10.1016/s0002-9394(02)01327-2. View

Yang J, Zhang Q, Chang H, Cheng Y . Surface-engineered dendrimers in gene delivery. Chem Rev. 2015; 115(11):5274-300. DOI: 10.1021/cr500542t. View

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000; 65(1-2):271-84. DOI: 10.1016/s0168-3659(99)00248-5. View

Billingsley M, Singh N, Ravikumar P, Zhang R, June C, Mitchell M . Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering. Nano Lett. 2020; 20(3):1578-1589. PMC: 7313236. DOI: 10.1021/acs.nanolett.9b04246. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T . Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014; 194:228-37. DOI: 10.1016/j.jconrel.2014.09.005. View

10.

Carpentier A, Canney M, Vignot A, Reina V, Beccaria K, Horodyckid C . Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci Transl Med. 2016; 8(343):343re2. DOI: 10.1126/scitranslmed.aaf6086. View

11.

Wente S . Gatekeepers of the nucleus. Science. 2000; 288(5470):1374-7. DOI: 10.1126/science.288.5470.1374. View

12.

Mello C, Conte Jr D . Revealing the world of RNA interference. Nature. 2004; 431(7006):338-42. DOI: 10.1038/nature02872. View

13.

Welch J, Dean D, Nilsson B . Synthesis and Application of Peptide-siRNA Nanoparticles from Disulfide-Constrained Cyclic Amphipathic Peptides for the Functional Delivery of Therapeutic Oligonucleotides to the Lung. Methods Mol Biol. 2020; 2208:49-67. DOI: 10.1007/978-1-0716-0928-6_4. View

14.

Yue J, Pallares R, Cole L, Coughlin E, Mirkin C, Lee A . Smaller CpG-Conjugated Gold Nanoconstructs Achieve Higher Targeting Specificity of Immune Activation. ACS Appl Mater Interfaces. 2018; 10(26):21920-21926. PMC: 6101240. DOI: 10.1021/acsami.8b06633. View

15.

Chen X, Gao H, Deng Y, Jin Q, Ji J, Ding D . Supramolecular Aggregation-Induced Emission Nanodots with Programmed Tumor Microenvironment Responsiveness for Image-Guided Orthotopic Pancreatic Cancer Therapy. ACS Nano. 2020; 14(4):5121-5134. DOI: 10.1021/acsnano.0c02197. View

16.

Perry J, Reuter K, Luft J, Pecot C, Zamboni W, DeSimone J . Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location. Nano Lett. 2017; 17(5):2879-2886. PMC: 5708115. DOI: 10.1021/acs.nanolett.7b00021. View

17.

Mitchell M, Billingsley M, Haley R, Wechsler M, Peppas N, Langer R . Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2020; 20(2):101-124. PMC: 7717100. DOI: 10.1038/s41573-020-0090-8. View

18.

Wu C, Han D, Chen T, Peng L, Zhu G, You M . Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. J Am Chem Soc. 2013; 135(49):18644-50. PMC: 3891927. DOI: 10.1021/ja4094617. View

19.

He H, Du L, Guo H, An Y, Lu L, Chen Y . Redox Responsive Metal Organic Framework Nanoparticles Induces Ferroptosis for Cancer Therapy. Small. 2020; 16(33):e2001251. DOI: 10.1002/smll.202001251. View

20.

Colombo M, Carregal-Romero S, Casula M, Gutierrez L, Morales M, Bohm I . Biological applications of magnetic nanoparticles. Chem Soc Rev. 2012; 41(11):4306-34. DOI: 10.1039/c2cs15337h. View